Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the implications of ibrutinib’s approval for patients with mantle cell lymphoma (MCL).
- Prior to ibrutinib’s approval, patients with MCL had no additional options once they failed their first induction therapy.
- Most patients with MCL are over age 65 and are therefore not candidates for transplant. These patients were previously treated with some sort of induction chemotherapy like R-CHOP followed by rituximab maintenance therapy.
- Before ibrutinib, younger patients with MCL previously had no valid option following relapse from transplant and induction therapy, which are incorporated into one package.
- Ibrutinib is beneficial to patients with MCL as it is an oral drug that has demonstrated a durable response rate with minimal side effects.